Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is an observational prospective study. The aim is to assess the prevalence of test positivity (swab or serological examination) to Coronavirus Disease-2019 (Covid-19) in relation to the duties and related occupational risk.
Description: Desciption of the prevalence of test positivity (swab or serological examination) in relation to the duties and related occupational risk
Measure: Prevalence of test positivity Time: Until the end of the study (approximately 6 months).Description: Description of the positive result of the test (swab or serological examination) with the manifestations of the signs / symptoms collected in the previous months from the attached form in the cohort of positive cases and related negative controls.
Measure: Correlation of the positive result of the test with the manifestations of the signs Time: Until the end of the study (approximately 6 months).Description: Description of the outcome of positive serological and swab test operators in terms of development of COVID-related symptomatology
Measure: Development of COVID Time: Until the end of the study (approximately 6 months).Description: to correlate the virus genomic sequence of asymptomatic but positive serological and swab operators with the available data of the SARS-CoV-2 virus sequences.
Measure: Analysis of genomic sequences of the virus Time: Until the end of the study (approximately 6 months).Description: Evaluate the relevance of tests with greater sensitivity and specificity in the population negative for the throat swab but positive for the serological investigation;
Measure: Evaluation of the test relevance Time: Until the end of the study (approximately 6 months).Description: Evaluation biomolecular markers that are predictive of susceptibility to infection and predictive of symptomatic infection
Measure: Evaluation of predictive biomolecular markers Time: Until the end of the study (approximately 6 months).Description: Evaluate the trend over time of the antibody response in subjects positive to the serological test and to the swab (both symptomatic and asymptomatic).
Measure: The trend over time of the antibody response in subjects positive Time: Until the end of the study (approximately 6 months).Description: Evaluate the frequency of re-infection (symptomatology compatible with COVID and positive swab) in operators who tested positive for serological and swab tests.
Measure: The frequency of re-infection Time: Until the end of the study (approximately 6 months).Description: Evaluate the mode of transmission between relatives by collecting anamnestic data.
Measure: Evaluation of the mode of transmission relatively anamnestic data Time: Until the end of the study (approximately 6 months).Description: Assess the mode of transmission between relatives by collecting the available clinical documentation
Measure: The relation between mode of transmission and the available clinical documentation Time: Until the end of the study (approximately 6 months).Description: Evaluate the mode of transmission between relatives by collecting the barriers used in the home: none, mask and spacing, voluntary isolation.
Measure: Evaluation of the mode of transmission for the use of barriers Time: Until the end of the study (approximately 6 months).Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports